Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Congenital Adrenal Hyperplasia Treatment Drug Market to Exhibit Immense Growth During the Study Period (2019-2032), Predicts DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

21 Dec, 2023, 22:01 GMT

Share this article

Share toX

Share this article

Share toX

The dynamics of the congenital adrenal hyperplasia market are anticipated to change in the coming years owing to the improvement in the research and development undertaking. In addition, persistently rising cases of CAH in the forecast period will contribute to the rise in the CAH treatment market.

LAS VEGAS, Dec. 21, 2023 /PRNewswire/ -- DelveInsight's Congenital Adrenal Hyperplasia Market Insights report includes a comprehensive understanding of current treatment practices, congenital adrenal hyperplasia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Congenital Adrenal Hyperplasia Market Report

  • As per DelveInsight analysis, the total congenital adrenal hyperplasia market size in the 7MM is ~USD 21 million in 2021 and is projected to increase during the forecast period (2023–2032).
  • As per DelveInsight estimates, the total 7MM diagnosed prevalent cases of CAH in 2021 were more than 73K out of which the maximum cases were seen in the US. 
  • Leading congenital adrenal hyperplasia companies such as Crinetics Pharmaceuticals Inc., Diurnal Limited, Adrenas Therapeutics Inc, Neurocrine Biosciences, Spruce Biosciences, and others are developing novel congenital adrenal hyperplasia drugs that can be available in the congenital adrenal hyperplasia market in the coming years.
  • The promising congenital adrenal hyperplasia therapies in the pipeline include CRN04894, Chronocort, AAV BBP-631, Crinecerfont, Tildacerfont, and others.

Discover which therapies are expected to grab the major congenital adrenal hyperplasia market share @ Congenital Adrenal Hyperplasia Market Report

Congenital Adrenal Hyperplasia Overview

Congenital adrenal hyperplasia (CAH) constitutes a rare cluster of autosomal recessive disorders stemming from an inherited deficiency in enzymes crucial for the production of specific hormones. The adrenal glands, nestled atop each kidney, play a pivotal role in synthesizing corticosteroids, mineralocorticoids, and androgens, with the absence of the enzyme 21-hydroxylase emerging as the primary cause of CAH. Certain forms of CAH warrant prenatal diagnosis methods like amniocentesis and CVS. Genetic testing takes precedence in scenarios involving pre-pregnancy genetic counseling, confirmation of diagnosis through blood hormone tests by an endocrinologist, or when hormone test results lack precision. Conversely, examinations encompassing genital, blood, and urine tests are employed to assess the production of hormones by the adrenal glands.

Congenital Adrenal Hyperplasia Epidemiology Segmentation

United States has the highest number of age-specific CAH cases (more than 9K cases in <18 years age group and around 22K cases in ≥18 years age group) in 2021, per DelveInsight's analysis. Furthermore, per Delveinsight's analysis, the age-specific cases of CAH are expected to increase by 2032.

The congenital adrenal hyperplasia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Congenital Adrenal Hyperplasia Diagnosed Prevalence
  • Congenital Adrenal Hyperplasia Age-specific Cases
  • Congenital Adrenal Hyperplasia Mutations-based Cases
  • Type-specific Cases of Classical Congenital Adrenal Hyperplasia 

Congenital Adrenal Hyperplasia Treatment Market 

While there is currently no cure for CAH, available treatments aim to alleviate associated congenital adrenal hyperplasia symptoms. Hormone replacement medications play a crucial role, elevating deficient hormone levels and moderating excess male hormone production. Individuals with classic CAH often require lifelong hormone medication, whereas those with milder forms may, in some cases, discontinue treatment in adulthood and maintain lower-dose regimens. Some individuals with non-classic CAH may not necessitate any form of congenital adrenal hyperplasia treatment.

Glucocorticoid replacement therapy aims to replace deficient steroids, control excess adrenal sex hormones and glucocorticoids, prevent virilization, optimize growth, and support fertility. The treatment of choice for growing children involves oral hydrocortisone tablets, while the use of hydrocortisone suspension is advised against. In cases of CAH, the primary approach to glucocorticoid replacement therapy typically utilizes oral hydrocortisone (10–15 mg/m2/24 h), administered in two or three divided doses per day.

For individuals diagnosed with the salt-wasting form of 21-OHD CAH, it is essential to undergo treatment involving 9α-fludrohydrocortisone (Florinef) at a daily dosage of 0.05–0.2 mg orally, along with sodium chloride supplementation at a rate of 1–2 g/day added to formula or foods. It is advisable for all individuals with the classic form of CAH to receive combined treatment with both 9α-fludrohydrocortisone and sodium chloride supplements during the newborn and early infancy stages.

To know more about congenital adrenal hyperplasia treatment guidelines, visit @ Congenital Adrenal Hyperplasia Management 

Congenital Adrenal Hyperplasia Pipeline Therapies and Key Companies

  • CRN04894: Crinetics Pharmaceuticals Inc.
  • Chronocort: Diurnal Limited
  • AAV BBP-631: Adrenas Therapeutics Inc
  • Crinecerfont: Neurocrine Biosciences
  • Tildacerfont: Spruce Biosciences

Learn more about the FDA-approved drugs for congenital adrenal hyperplasia @ Drugs for Congenital Adrenal Hyperplasia Treatment 

Congenital Adrenal Hyperplasia Market Dynamics

The dynamics of the congenital adrenal hyperplasia are expected to change in the coming years. In developed countries worldwide, prenatal and newborn screening programs for CAH disease have been successfully implemented, facilitating early detection and treatment in children. Ongoing research and therapeutic trials exploring novel molecules like selective corticotropin-releasing factor type 1-receptor inhibitors, gene therapy, and ACAT-1 inhibitors are yielding promising outcomes. A novel extended therapy approach is being explored to address the long-term side effects, complications, and circadian rhythm insufficiency associated with glucocorticoids and mineralocorticoids. Although the current treatment primarily targets patients with 21-hydroxylase insufficiency, potential research on atypical CAH variations is expected to open avenues for treating rare types in the future.

Furthermore, the congenital adrenal hyperplasia pipeline is very robust; many potential therapies are being investigated for the treatment of congenital adrenal hyperplasia, and it is safe to predict that the treatment space will significantly impact the congenital adrenal hyperplasia market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the congenital adrenal hyperplasia market in the 7MM.

However several factors may impede the growth of the congenital adrenal hyperplasia market. The diagnosis of non-classical CAH may not occur until a person begins to show symptoms in later stages of life. CAH can be misdiagnosed with other diseases such as Addison's disease, Ovotesticular disorder, and Turner syndrome. Furthermore, gene therapy, while promising, is costly; moreover, the health system in most countries, including the US, is not set up for large one-time payments. In comparison to small molecules, gene therapies take a longer time for their approval, and the approval guidelines for gene therapies are not as well defined as those for small molecules or monoclonal antibodies.

Moreover, congenital adrenal hyperplasia treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the congenital adrenal hyperplasia market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the congenital adrenal hyperplasia market growth.

Congenital Adrenal Hyperplasia Market Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Congenital Adrenal Hyperplasia Market Size in 2021

USD 21 Million

Key Congenital Adrenal Hyperplasia Companies

Crinetics Pharmaceuticals Inc., Diurnal Limited, Adrenas Therapeutics Inc, Neurocrine Biosciences, Spruce Biosciences, and others

Key Pipeline Congenital Adrenal Hyperplasia Therapies

CRN04894, Chronocort, AAV BBP-631, Crinecerfont, Tildacerfont, and others

Scope of the Congenital Adrenal Hyperplasia Market Report

  • Therapeutic Assessment: Congenital Adrenal Hyperplasia current marketed and emerging therapies
  • Congenital Adrenal Hyperplasia Market Dynamics: Key Market Forecast Assumptions of Emerging Congenital Adrenal Hyperplasia Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Congenital Adrenal Hyperplasia Market Access and Reimbursement

Discover more about congenital adrenal hyperplasia drugs in development @ Congenital Adrenal Hyperplasia Clinical Trials

Table of Contents

1.

Congenital Adrenal Hyperplasia Key Insights

2.

Congenital Adrenal Hyperplasia Report Introduction

3.

Congenital Adrenal Hyperplasia Overview at a Glance

4.

Congenital Adrenal Hyperplasia Executive Summary

5

Congenital Adrenal Hyperplasia Key Events

6

Epidemiology and Market Forecast Methodology

6.

Disease Background and Overview

7.

Congenital Adrenal Hyperplasia Treatment and Management

8.

Congenital Adrenal Hyperplasia Guidelines

9.

Congenital Adrenal Hyperplasia Epidemiology and Patient Population

10.

Patient Journey

11.

Key Endpoints in Congenital Adrenal Hyperplasia 

12.

Congenital Adrenal Hyperplasia Marketed Drugs

13.

Congenital Adrenal Hyperplasia Emerging Drugs

14.

7MM Congenital Adrenal Hyperplasia Market Analysis

15.

Market Access and Reimbursement

16.

KOL Views

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Related Reports

Congenital Adrenal Hyperplasia Pipeline

Congenital Adrenal Hyperplasia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key congenital adrenal hyperplasia companies, including Neurocrine Biosciences, Spruce Biosciences, Adrenas Therapeutics Inc, Crinetics Pharmaceuticals, Diurnal, among others.

Congenital Adrenal Hyperplasia Epidemiology Forecast

Myocardial Infarction Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted congenital adrenal hyperplasia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Adrenal Crisis Market

Adrenal Crisis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key adrenal crisis companies including Eton Pharmaceuticals, Antares Pharma, among others.

Adrenal Crisis Pipeline

Adrenal Crisis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key adrenal crisis companies, including Eton Pharmaceuticals, Antares Pharma, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com   
+91-9650213330
www.delveinsight.com   

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Modal title

Also from this source

Essential Thrombocythemia Market to Witness Robust Growth During the Forecast Period (2025-2034) Amid Rising R&D Activity | DelveInsight

Essential Thrombocythemia Market to Witness Robust Growth During the Forecast Period (2025-2034) Amid Rising R&D Activity | DelveInsight

Essential thrombocythemia is a chronic form of myeloproliferative neoplasm (MPN) marked by an abnormally high platelet count in the bloodstream. It...

Angelman Syndrome Market to Witness Significant Growth Through 2034, Driven by Novel Therapeutic Advancements | DelveInsight

Angelman Syndrome Market to Witness Significant Growth Through 2034, Driven by Novel Therapeutic Advancements | DelveInsight

Angelman syndrome is a rare neurogenetic disorder affecting approximately 1 in 15,000 live births or 500,000 people globally. It results from the...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.